An official website of the United States government
Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
FDA has approved and authorized 2024–2025 Moderna and Pfizer-BioNTech COVID-19 vaccines. CDC recommendations for use of these vaccines in people ages 6 months and older can be found below.
The 2023–2024 Novavax COVID-19 Vaccine remains authorized but is no longer available in the United States as all doses have expired. Accordingly, at this time, CDC recommendations for use of Novavax COVID-19 Vaccine have been removed from the Interim Clinical Considerations. This page will be updated if FDA approves or authorizes additional 2024–2025 COVID-19 vaccines.
Recommendations for 2024–2025 Moderna COVID-19 Vaccine and 2024–2025 Pfizer-BioNTech COVID-19 Vaccine
People who are not moderately or severely immunocompromised
Initial vaccination
- Ages 6 months–4 years
- 2 doses of 2024–2025 Moderna or 3 doses of 2024–2025 Pfizer-BioNTech
- Ages 5 years and older
- 1 dose of 2024–2025 Moderna or 1 dose of 2024–2025 Pfizer-BioNTech
Received previous doses of a COVID-19 vaccine
- Ages 6 months–4 years
- 1 or 2 doses of 2024–2025 mRNA vaccine from the same manufacturer as administered for initial vaccination, depending on the vaccine and the number of prior doses
- Ages 5 years and older
- 1 dose of 2024–2025 Moderna or 1 dose of 2024–2025 Pfizer-BioNTech
Additional dose: An additional dose of 2024–2025 COVID-19 vaccine for people ages 65 years and older who are not moderately or severely immunocompromised is NOT currently recommended.
People who are moderately or severely immunocompromised
Initial vaccination
- Ages 6 months and older
- 3 doses of 2024–2025 Moderna or 3 doses of 2024–2025 Pfizer-BioNTech
Received previous doses of a COVID-19 vaccine
- Recommended mRNA vaccine and number of 2024–2025 doses are based on age and vaccination history
Additional doses: People who are moderately or severely immunocompromised ages 6 months and older may receive 1 or more age-appropriate doses of a 2024–2025 mRNA COVID-19 vaccine.
Receive email updates about this page.